Moderna, an early-stage biotech developing therapies based on its modified mRNA platform, raised $604 million by offering 26.3 million shares at $23, the midpoint of the $22 to $24 range. The company offered additional shares to raise 21% more than originally planned. At pricing, Moderna commands a fully diluted market value of $8.1 billion.
Moderna plans to list on the Nasdaq under the symbol MRNA. Morgan Stanley, Goldman Sachs, J.P. Morgan, BofA Merrill Lynch, Barclays and Piper Jaffray acted as lead managers on the deal.
